JAAFR INTERNATIONAL RESEARCH JOURNAL
JOURNAL OF ADVANCE AND FUTURE RESEARCH
JAAFR.ORG | ISSN : 2984-889X
An International Open Access, Peer-reviewed, Refereed Journal

"A Review On Topical Ketoconazole Mechanisms Of Action, spectrum of activity and advances in dermatological uses"

Giri Khushboo, Soebkhan Lakhara, Saif masi, Piyush rabari, Sahil qureshi

1. School of Pharmacy, Rai University, Ahmedabad- 382260, INDIA

*Corresponding Author:

Khushboo Babloo Giri

Department School of Pharmacy Qualifications with Class Grade

B.Pharm, Rai University, Ahmedabad 382260, INDIA

1. ABSTRACT

Ketoconazole is a synthetic imidazole antifungal agent introduced in the early 1980s as one of the first orally active azole compounds for systemic fungal infections. Although its systemic use has declined over the years due to safety concerns and the emergence of newer triazole antifungals, ketoconazole remains clinically relevant, particularly in its topical formulations. It is widely used in dermatology for treating superficial fungal infections, seborrheic dermatitis, and pityriasis versicolor. Its broad antifungal activity, combined with additional anti- inflammatory and anti-androgenic effects, makes it a versatile therapeutic agent

The primary mechanism of action of ketoconazole involves the inhibition of the fungal cytochrome P450 enzyme lanosterol 14-α-demethylase. This enzyme catalyzes a critical step in converting lanosterol to ergosterol. Ketoconazole binds to the heme iron of the enzyme and blocks this demethylation reaction. As a result, ergosterol levels decline, and toxic sterol intermediates accumulate within the membrane. These alterations disrupt membrane permeability, impair nutrient transport, and inhibit fungal growth. While this activity is primarily fungistatic, it can be fungicidal at higher concentrations or against particularly susceptible species.

Keywords : KetoconazolTopical, antifungalMechanism of action, Ergosterol inhibition, Fungal cell membrane, Spectrum of activity Dermatophytes, Candida Malassezia, Dermatological usesSeborrheic,dermatitisTinea infections, Antiinflammatory effects,Emerging application, Resistance profile.

2. INTRODUCTION

Ketoconazole is a synthetic imidazole antifungal agent introduced into clinical practice in the early 1980s as one of the first orally active azole compounds for systemic fungal infections. Although its systemic use has declined over the years due to safety concerns and the emergence of newer triazole antifungals, ketoconazole remains clinically relevant, particularly in its topical formulations. It finds wide application in dermatology for the treatment of superficial fungal infections, seborrheic dermatitis, and pityriasis versicolor. Its broad antifungal activity, further combined with additional anti-inflammatory and anti-androgenic effects, makes it a versatile therapeutic agent.

Structurally, ketoconazole is an azole antifungal that exerts its antifungal activity via interference with the synthesis of ergosterol. Ergosterol is a vital sterol component of fungal cell membranes, just like cholesterol in human cells, which plays a very important role in maintaining membrane fluidity, integrity, and proper functioning of membrane-bound enzymes. The interference with the synthesis of this important molecule compromises not only fungal cellular processes but ultimately inhibits growth or leads to cell death. Its ability to compromise fungal membrane structure underlies its efficacy across a variety of pathogenic fungi.

The central mechanism of action of ketoconazole is the inhibition of the fungal cytochrome P450 enzyme lanosterol 14-α-demethylase, which catalyzes a critical step in the conversion of lanosterol to ergosterol. Ketoconazole binds to the heme iron of the enzyme and prevents this demethylation reaction. Consequently, ergosterol levels fall and toxic sterol intermediates accumulate within the membrane. These changes disrupt membrane permeability, impair nutrient transport, and inhibit fungal growth. Although this action is principally fungistatic, it becomes fungicidal at higher concentrations or against particularly susceptible species. In addition to this central effect on sterol synthesis, ketoconazole impairs several fungal cytochrome P450–dependent processes and thereby exerts its broad activity. However, this mechanism also partly explains its adverse effect profile in systemic use, since it can inhibit human steroidogenic pathways at therapeutic doses.

Ketoconazole has a wide spectrum of activity against fungi. It acts against dermatophytes such as Trichophyton, Microsporum, and Epidermophyton species, thus being used in the treatment of skin, hair, and nail tinea infections. This drug is also active against a range of yeasts including, most notably, Candida species and Malassezia furfur, responsible for mucocutaneous candidiasis and pityriasis versicolor, respectively. Furthermore, ketoconazole is active against some dimorphic fungi, for example, Histoplasma capsulatum and Blastomyces dermatitidis, although systemic treatment of these conditions has, to a large extent, been superseded by safer agents like itraconazole.

Topically, ketoconazole is very effective because of high local concentrations and minimal systemic absorption. This makes it a preferred option for long-term or recurrent superficial fungal infections, especially when anti-inflammatory or anti- seborrheic effects are beneficial. Ketoconazole remains a highly useful antifungal drug based on its well-characterized mechanism, broad activity against dermatophytes and yeasts, and its significant role in topical therapy. Systemic use has fallen off, but its pharmacologic properties continue to support important clinical applications in managing superficial fungal disorders.

3. ADVANCED DELIVERY SYSTEM FOR KETOCONAZOLE

Advanced delivery systems were developed for ketoconazole, overcoming the drawbacks of conventional topical formulations, including poor solubility, inadequate penetration through the stratum corneum, and unpredictable therapeutic outcome. Due to the very lipophilic nature of the ketoconazole molecule, an enhancement of delivery to deeper skin layers and into hair follicles is a definite need for the treatment of conditions dominated by both Malassezia and dermatophytes.Modern technologies have focused on improving drug solubilization, maximizing local bioavailability, reducing irritation, and ensuring sustained release. Several innovative systems have demonstrated significant benefits in dermatological applications.

Among the most explored advanced systems are nanoemulsions, which are ultrafine oil droplets stabilized by mild surfactants. The nanometer-sized droplets allow ketoconazole to remain solubilized and well-dispersed, with marked improvement in permeation through the skin barrier. Nanoemulsions are able to enhance the delivery of drugs into pilosebaceous units, serving as reservoirs for fungal organisms. This light, quickly absorbed lotion without greasiness also enhances patient compliance and makes these nanoemulsions promising for long- term management of seborrheic dermatitis.

Microemulsion represents another effective delivery system, in which oil, water, surfactants, and co-surfactants form an isotropic, thermodynamically stable mixture. High ketoconazole solubility induces increased permeation and homogeneous distribution in the skin. Because of inherent stability and easy preparation, microemulsions are suitable for large-surface fungal infections, such as pityriasis versicolor. The hydrating effect of microemulsions further facilitates drug permeation into the stratum corneum.

Lipid-based nanocarriers, particularly liposomes, SLNs, and NLCs, represent more sophisticated delivery options. Liposomes use phospholipid bilayers similar to biological membranes, thus allowing fusion with skin lipids and providing controlled drug release. The result is deeper penetration with lower irritation, making liposomal ketoconazole suitable for sensitive facial areas.

Foam formulations have also emerged as practical delivery systems for ketoconazole. Their low-density, pressurized vehicle spreads easily across hair- bearing areas like the scalp and beard, areas that are traditionally challenging for creams or lotions. Foams enhance patient adherence because they dry quickly, leave minimal residue, and allow uniform drug coverage, particularly important in seborrheic dermatitis and scalp pityriasis versicolor.

Another emerging approach involves cyclodextrin inclusion complexes, which encapsulate ketoconazole within hydrophilic macrocyclic molecules. This technique enhances aqueous solubility and stability while reducing the need for irritating solvents such as alcohols. Cyclodextrin-based systems are suitable for sensitive or inflamed skin and can be incorporated into clear gels, sprays, or aqueous solutions.

Lastly, hydrogel-based and bioadhesive delivery systems enhance drug retention at the site of application while minimizing irritation. Hydrogels maintain a moist environment that supports drug diffusion, while bioadhesive polymers ensure prolonged contact with skin surfaces prone to movement or moisture, such as intertriginous areas.Foam formulations have also emerged as practical delivery systems for ketoconazole. A low-density, pressurized vehicle that spreads easily across hair-bearing areas like the scalp and beard, traditionally difficult to treat with creams or lotions, improves patient compliance with quick drying, minimal residue, and uniform drug coverage, and is of particular importance in seborrheic dermatitis and scalp pityriasis versicolor.

Another novel strategy includes cyclodextrin inclusion complexes that encapsulate ketoconazole in hydrophilic macrocyclic molecules. This significantly improves aqueous solubility and stability with reduced dependence on irritating solvents like alcohols. Systems containing cyclodextrin are suitable for sensitive or inflamed skin and can be incorporated into clear gels, sprays, or aqueous solutions.

Hydrogel-based and bioadhesive delivery systems ensure better drug retention at the site of application with minimal irritation. The hydrogels maintain a moist environment supporting drug diffusion, while the bioadhesive polymers assure an extended contact time with skin surfaces that are often subjected to motion or moisture, like intertriginous areas.

Advanced delivery systems significantly improved the therapeutic potential of ketoconazole by enhancing its solubility, dermal penetration, sustained release, and patient acceptability. Nanoemulsions, microemulsions, lipid-based nanocarriers, foams, cyclodextrin complexes, and hydrogels are major innovations of this approach, which promises better results in modern dermatological therapy.

In summary, advanced delivery systems have significantly expanded the therapeutic potential of ketoconazole by improving solubility, dermal penetration, sustained release, and patient acceptability. Nanoemulsions, microemulsions, lipid- based nanocarriers, foams, cyclodextrin complexes, and hydrogels represent key innovations driving superior outcomes in modern dermatological therapy.

4. MECHANISM OF ACTIVITY

Ketoconazole is a synthetic imidazole compound whose biological activity spans both antifungal and endocrine systems through its ability to inhibit lipid and sterol biosynthesis in fungi and to block multiple cytochrome P450-dependent pathways in humans. In fungi, ketoconazole disrupts the biosynthesis of essential membrane lipids, including phospholipids and triglycerides, by interfering with endoplasmic-reticulum-based enzymatic pathways responsible for fatty acid assembly, glycerolipid production, and the formation of phosphatidic acid, which is the precursor of major phospholipid classes required for bilayer integrity. More critically, ketoconazole inhibits the P450 enzyme lanosterol 14-α-demethylase (CYP51), a key catalyst in the sterol synthesis pathway that converts lanosterol to ergosterol, the principal fungal membrane sterol. Through high-affinity binding of its imidazole nitrogen to the heme iron of CYP51, ketoconazole prevents molecular oxygen from interacting with the enzyme's catalytic site, thereby blocking demethylation of lanosterol and causing the accumulation of aberrant 14- methyl sterols that disrupt cellular architecture. Because ergosterol is essential for maintaining proper membrane fluidity, permeability, and structural stability, its depletion leads to excessive membrane fluidity, impaired lipid packing, and weakened barrier function, resulting in uncontrolled leakage of ions and metabolites. The loss of ergosterol also destabilizes sterol-rich microdomains needed for protein anchoring, thereby compromising nutrient transporters, proton pumps, efflux systems, and electron-transport proteins. As a consequence, fungal cells experience oxidative stress, mitochondrial dysfunction, failed cytokinesis, and eventually loss of viability. Beyond its antifungal actions, ketoconazole affects human steroid hormone synthesis by inhibiting several steroidogenic cytochrome P450 enzymes, most notably 17-α-hydroxylase and 17,20-lyase (both activities of CYP17A1), which are essential for producing adrenal and gonadal androgens such as dehydroepiandrosterone (DHEA), androstenedione, testosterone, and
dihydrotestosterone. In addition, ketoconazole inhibits 21-hydroxylase (CYP21A2),
which is required for converting progesterone and 17-hydroxyprogesterone into 11-deoxycorticosterone and 11-deoxycortisol, the immediate Apart from enzymatic inhibition, ketoconazole is a weak competitive antagonist of the androgen receptors, binding to receptor sites that would normally be occupied by testosterone and dihydrotestosterone, thus reducing receptor-mediated gene activation, contributing to the decreased androgen signaling in tissues such as the
prostate. The combined effect of these endocrine actions is a profound reduction in circulating androgens and glucocorticoids, explaining ketoconazole's clinical utility in the treatment of androgen-dependent prostate cancer and hypercortisolemic disorders such as Cushing's syndrome. However, these same mechanisms also underlie its endocrine-related adverse effects, including gynecomastia, reduced libido, menstrual irregularities, and potential adrenal insufficiency. Altogether, the multifaceted biochemical effects of ketoconazole-from disruption of fungal lipid and sterol metabolism to inhibition of human steroidogenesis-make it a drug of significant mechanistic complexity and clinical relevance, even as its systemic use has diminished due to concerns about hepatotoxicity and safer alternative therapies.

5. SPECTRUM OF ACTION

Topical ketoconazole is one of the most commonly used imidazoles in dermatology due to its wide antifungal spectrum. Its action encompasses a wide range of superficial fungal pathogens, such as yeasts, dermatophytes, and certain nondermatophyte molds. Besides its antifungal action, ketoconazole has other anti- inflammatory and anti-seborrheic properties that are of therapeutic value in the management of several cutaneous disorders. The detailed spectrum of its action is discussed below.

1. Activity Against Malassezia Species

Ketoconazole is particularly effective against Malassezia, the lipophilic yeast implicated in seborrheic dermatitis, pityriasis versicolor, and Malassezia folliculitis.

It disrupts ergosterol synthesis, leading to rapid collapse of fungal cell membranes.

Malassezia globosa and M. restricta, the primary species implicated in dandruff and seborrheic dermatitis, are highly sensitive to ketoconazole.

Topical formulation, like shampoos and foams, yields high local concentration that inhibits the overgrowth of yeasts, cuts down inflammatory cytokine release, and, thus, restores the balance of scalp microbiome.

This strong Malassezia activity is the cornerstone of the use of ketoconazole in chronic scalp disorders.

2. Activity Against Candida Species

Ketoconazole possesses strong activity against various Candida species, including
C. albicans, C. tropicalis, C. krusei, and C. parapsilosis.

It is effective for cutaneous candidiasis, especially intertriginous infections, where moisture encourages the proliferation of yeasts.

Its anti-inflammatory action helps in relieving erythema, maceration, and itching associated with Candida-infected folds.

Topical preparations ensure sufficient concentrations, even in humid conditions, for a consistent therapeutic effect.

3. Activity Against Dermatophytes

Although oral ketoconazole is no longer in common use, topical ketoconazole maintains efficacy against the following dermatophytes:

Trichophyton rubrum

T. mentagrophytes Epidermophyton floccosum Microsporum species

Ketoconazole interferes with fungal membrane integrity, leading to leakage of intracellular components.

Topical forms are considered effective for mild forms of tinea corporis, tinea cruris, and tinea faciei, though dermatophytes may require longer courses of treatment than yeasts.

Although not the first-line therapy for dermatophytosis, ketoconazole remains useful in those patients intolerant of allylamines or azoles such as clotrimazole.

4. Activity Against Non-Dermatophyte Molds

Its activity against nondermatophyte molds is narrower and more variable.

Some sensitivity is noted in species such as Aspergillus and Penicillium, but higher concentrations are required.

Ketoconazole is generally considered to be supportive rather than primary therapy for clinically significant mold infections.

5. Anti-Inflammatory and Antimicrobial Effects Beyond Fungi

Topical ketoconazole exhibits additional biological activities that indirectly widen its spectrum of action:

Anti-inflammatory action: through decreased production of prostaglandins and leukotrienes, it relieves erythema and pruritus in seborrheic dermatitis.

Mild antibacterial action: possesses inhibitory action against gram-positive bacteria implicated in folliculitis and exacerbation of seborrheic dermatitis, but this is secondary to its antifungal action.

Sebum-modulating properties may decrease scalp oiliness, further limiting Malassezia colonization.

6. Spectrum Summary

Pathogen Group Activity Level Clinical Relevance
Malassezia spp. Very high Seborrheic dermatitis, dandruff, pityriasis versicolor Candida spp. High Intertrigo, mucocutaneous candidiasis Dermatophytes Moderate Tinea corporis, cruris, faciei (mild–moderate cases) Nondermatophyte moldsVariableLimited or adjunctive use Bacteria (e.g., Staphylococcus) Low–moderate Supportive, not primary therapy.

6. COMPARISON OF KETOCONAZOLE WITH NEWER ANTIFUNGAL

Newer antifungal agents developed to overcome limitations of safety and efficacy associated with ketoconazole include fluconazole, itraconazole, voriconazole, and posaconazole. Unlike ketoconazole, which is a strong inhibitor of human cytochrome P450 enzymes, these newer azoles exhibit greater enzyme selectivity, which results in fewer endocrine effects and a significantly reduced risk of hepatotoxicity. Fluconazole and itraconazole have improved oral bioavailability and more predictable absorption than does ketoconazole, whereas voriconazole and posaconazole have a broader spectrum of activity against resistant Candida and Aspergillus species. The modern forms of these medications use an advanced delivery system such as triazole structures and/or lipid-based carriers to enhance tissue penetration and reduce toxicity. These characteristics have made the newer antifungals safer and more effective in systemic infections, leading to a major decline in systemic administration of ketoconazole. Currently, ketoconazole is used primarily in topical applications, whereas newer agents remain the drug of choice for invasive and long-term antifungal therapy. Clinical uses of ketoconazole:

topical treatments:

Dermatophytosis:

Ketoconazole is widely used in topical formulations like creams.

7. CLINICAL USES OF KETOCONAZOLE

Topical ketoconazole has become one of the commonly prescribed dermatological treatments due to its broad antifungal activity, favorable tolerability, and efficacy in disorders related to Malassezia and other pathogenic fungi. The main clinical indication is the treatment of seborrheic dermatitis: a chronic inflammatory disease of the scalp, face, and trunk. Ketoconazole shampoos and creams are effective by removing the Malassezia species and reducing the associated inflammation, which helps alleviate symptoms that involve flaking, erythema, pruritus, and scalp scaling. It is a first-line treatment for dandruff, in which regular application decreases fungal colonization and restores scalp barrier function. The other major

indication is pityriasis versicolor, a superficial fungal infection manifested by hypo-or hyperpigmented patches on the trunk and shoulders. Since the condition is driven by an overgrowth of the resident lipophilic yeast Malassezia, topical ketoconazole creams, foams, and shampoos decrease the fungal burden and are able to prevent recurrence with intermittent maintenance therapy. Less common indications of topical ketoconazole include cutaneous candidiasis, such as intertrigo of moist skin folds, in which antifungal action maintains relief from erythema, maceration, and irritation. It is also used as adjuvant therapy in tinea corporis, tinea cruris, and other mild dermatophyte infections when the involvement is limited and systemic therapy is not required. Over the last years, ketoconazole has gained clinical relevance in treating Malassezia-associated facial dermatoses, such as certain forms of facial dermatitis and adult-onset atopic dermatitis exacerbated by yeast proliferation. Some clinicians also incorporate ketoconazole into treatment regimens for acneiform eruptions or folliculitis suspected to betriggered by Malassezia species, as the dru**g** helps reduce follicular colonization and inflammation. Advances in formulation technology—such as gels, foams, and enhanced-delivery shampoos—have expanded its clinical reach by improving penetration into sebaceous areas and hair follicles. These developments support both acute treatment and long-term maintenance, making topical ketoconazole a versatile and dependable therapy for a range of fungal and yeast-related dermatologic disorders.

8. PHARMACOKINETIC OF KETOCONAZOLE

The pharmacokinetics of topical ketoconazole are characterized by minimal systemic absorption and high localization within the superficial layers of the skin and hair follicles. When applied to intact skin, only a very small fraction penetrates beyond the epidermis, measurable plasma concentrations are usually undetectable or extremely low. This limited absorption reflects the drug's high lipophilicity, which favors retention within the stratum corneum and sebaceous-rich areas rather than passage into systemic circulation. After topical application, ketoconazole binds strongly to epidermal keratin and accumulates in the upper skin layers, creating a reservoir effect that supports sustained antifungal activity even after washing. The drug is slowly released from this reservoir, contributing to prolonged therapeutic action while minimizing systemic exposure. In scalp applications like shampoos, ketoconazole concentrates in hair follicles, where Malassezia species are abundant, thus enhancing its clinical effectiveness. Because systemic levels are negligible, topical ketoconazole undergoes very limited hepatic metabolism and does not meaningfully interact with systemic cytochrome P450 pathways.

Excretion of the minute absorbed fraction occurs primarily through biliary elimination. Overall, the profile of topical ketoconazole provides for high local potency, prolonged skin retention, and a favorable safety margin due to minimal systemic distribution.

9. PHARMACODYNAMICS OF KETCONAZOLE

Topical ketoconazole acts by the selective inhibition of a fungal enzyme, lanosterol 14-α-demethylase, which is an important component of the sterol synthesis pathway. Inhibition of this enzyme prevents ergosterol synthesis, an essential structural sterol of fungal cell membranes. As the levels of ergosterol fall and those of abnormal sterol intermediates accumulate, the membrane becomes fragile, loses its integrity to regulate permeability, and cannot support the growth of fungi. Apart from its primary antifungal action, ketoconazole also possesses secondary anti- inflammatory activity, believed to be due to the impaired synthesis of pro- inflammatory mediators. Its spectrum of activity mainly comprises dermatophytes like Trichophyton and Microsporum species, yeasts such as Candida, and especially Malassezia, making it very well suited for conditions like seborrheic dermatitis, dandruff, and pityriasis versicolor. The pharmacodynamics of topical ketoconazole are highlighted by the high drug concentrations attainable at the skin surface with minimal systemic absorption, enabling effective local action devoid of significant systemic effects. Recent advances in dermatology have been aimed at enhancing delivery and compliance. Newer formulations, like foams, gels, shampoos with enhanced stay time, and lipid-based carriers, facilitate greater penetration into hair follicles and sebaceous areas-harboring sites for Malassezia.

Improved vehicles afford longer residence time, better symptom control, and more convenient dosing. As a result, topical ketoconazole has moved from a topical antifungal agent to a versatile agent used in both active treatment and long-term maintenance of recurrent or inflammatory skin diseases associated with fungal overgrowth.

10. ADVERSE EFFECTS

ketoconazole, whether used topically or systemically, is associated with several adverse effects, although the severity and frequency differ markedly between formulations. Topical ketoconazole is generally well tolerated, with most adverse reactions being mild and localized. Common effects include transient erythema, burning, stinging, dryness, or pruritus at the application site. Some individuals may develop contact dermatitis, either irritant or allergic in nature, particularly with formulations containing alcohols, fragrances, or preservatives. Occasional changes in hair texture or oiliness may occur with shampoo preparations, and rare cases of abnormal hair shedding have been reported.

In contrast, systemic ketoconazole—now restricted or withdrawn for routine fungal infections in many countries—has been associated with more serious adverse effects. The most clinically significant is hepatotoxicity, ranging from asymptomatic elevation of liver enzymes to severe liver injury. Other systemic effects include gastrointestinal discomfort, headache, dizziness, and endocrine disturbances such as decreased testosterone production and reversible gynecomastia due to inhibition of steroid synthesis. Drug–drug interactions are also common, as ketoconazole inhibits CYP3A4, leading to potential accumulation of co-administered medications.

Although systemic toxicity is not a concern with routine topical use, awareness of both local and historical systemic adverse effects remains important for appropriate clinical decision-making.

11. FACTORS CONTRIBUTING TO KETOCONAZOLE TOXICITY

The toxicity profile of ketoconazole is of serious concern, especially the systemic form, for which use is considerably restricted in many parts of the world. Topical ketoconazole has a much safer profile; however, several factors contribute to the potential of local and systemic toxicity. Recognition of these factors is crucial to optimize the use of this drug therapeutically while minimizing any untoward effects.

One of the major determinants of ketoconazole toxicity is its inhibition of cytochrome P450 enzymes, especially CYP3A4. The systemic consequence of this is impaired metabolism of many drugs, increasing the potential for hepatotoxicity and adrenal suppression and for harmful drug-drug interactions. Although topical preparations result in minimal systemic absorption, prolonged use on compromised or inflamed skin may increase penetration and theoretically enhance systemic exposure.

Dose and length of therapy are also very important. With increased concentration and frequency of application, local irritation, erythema, burning, or pruritus can occur. During the period when systemic types were in wide use, prolonged therapy was associated with increased liver enzymes and, rarely, severe hepatic injury.

These findings from the past continue to influence cautious use even in topical settings.

Other contributing factors include individual patient susceptibility. Genetic variations in hepatic enzyme activity, pre-existing liver disease, or the administration of other hepatotoxic agents can enhance the risk of an adverse response. Age may also be an additional factor: infants and the elderly may have a reduced metabolic capacity and thereby be more susceptible to drug accumulation.

Formulation characteristics can affect toxicity as well. Alcohol-based solutions or vehicles containing strong surfactants may enhance irritation and/or skin barrier disruption while increasing absorption. On the other hand, newer formulations such as nanoemulsions and lipid-based carriers are designed to minimize irritation and avoid the use of harmful solvents.

Environmental and disease-related factors also play their part. The use of ketoconazole on large surface areas, under occlusion, or on severely inflamed skin greatly increases systemic absorption. Fungal infection of macerated or eroded skin further increases permeability and risk.

In summary, ketoconazole toxicity is multifactorial, with the combination of pharmacologic, patient-related, and formulation-specific factors. Awareness of these influences helps optimize safety, especially when modern research continues to refine low-toxicity topical delivery systems.

12. ADVANCEMENTS OF ANTIFUGAL AGENTS

Extensive research and clinical application of ketoconazole have significantly enhanced its position as one of the primary antifungal agents, especially in dermatology. While the drug has been on the market for many years, its mechanism of activity has become better understood, its antimicrobial spectrum has become wider, and its delivery is being enhanced with newly developed topical formulations.

One key advance has been the recognition of an expanded understanding of the molecular mechanism of action. Although traditionally it was primarily recognized as an inhibitor of fungal ergosterol synthesis, recent reports have detailed its specific interaction with the lanosterol 14-α-demethylase enzyme, CYP51. Enhanced structural modeling has provided even more insight on how ketoconazole binds to the heme group of CYP51 and thereby disrupts ergosterol production more effectively than was previously understood. This expanded mechanistic insight enhances its potent effect on yeasts, especially Malassezia species, which highly depend on intact membrane sterols. Its secondary anti- inflammatory effects, including actions reducing pro-inflammatory cytokines, have also been elucidated and further enhance outcomes in chronic inflammatory dermatoses such as seborrheic dermatitis.

Advancement has also refined our understanding of the spectrum of activity. Modern molecular techniques, including improved culturing and sequencing technologies, have expanded species-level data on Malassezia, showing ketoconazole to remain highly active against clinically dominant strains M. globosa, M. restricta, and M. furfur. New susceptibility studies have confirmed strong activity against most cutaneous Candida species and maintained effectiveness against dermatophytes in superficial infections. Updated in vitro assessments have mapped MICs more precisely, supporting ketoconazole's continued relevance against a broad range of fungal pathogens. One of the most impactful areas of advancement is topical formulation technology. Traditional creams and shampoos have now been supplemented by innovative delivery systems such as nanoemulsions, microemulsions, liposomes, SLNs, NLCs, and cyclodextrin complexes. These systems significantly enhance solubility, skin penetration, and drug retention while reducing irritation. Improved deposition in pilosebaceous units-especially important in Malassezia-related conditions-has enhanced therapeutic effectiveness, even with shorter contact times. Application convenience was further enhanced by foam formulations and hydrogels, which improve patient adherence in chronic scalp and facial dermatoses.

Also contributing to clinical advancements are the widened dermatologic uses of ketoconazole. This drug is not only a well-recognized treatment for various fungal infections but also an important alternative in seborrheic dermatitis, Malassezia folliculitis, pityriasis versicolor, and mixed inflammatory-fungal conditions. Its anti-androgenic and anti-inflammatory modes of action find new potential roles, as reported in ongoing research.

Overall, progress in mechanistic understanding, spectrum characterization, and delivery technologies has underpinned the continuing relevance of ketoconazole to contemporary dermatological therapy.

13. CONCLUSION

Ketoconazole remains an important milestone in the evolution of antifungal therapy, marking one of the earliest successful attempts to develop an orally active azole agent. Its ability to inhibit ergosterol synthesis established a strong foundation for understanding fungal cell membrane disruption and guided the development of subsequent antifungal classes. The literature indicates that ketoconazole had a broad-spectrum activity profile and played a very important role at a time when treatment options were limited. However, its use has slowly decreased systemically because of significant limitations related to its hepatotoxicity, hormonal disturbances, and extensive drug–drug interactions from its inhibition of human cytochrome P450 enzymes. As more modern antifungal agents with better profiles of safety, selectivity, and breadth became available, ketoconazole's clinical role was largely shifted to topical formulations, where it remains safe and effective. Overall, while ketoconazole is no longer preferred for systemic infections, it remains historically significant and continues to contribute meaningfully to dermatological therapy.

14. REFERENCES

1. Vanden Bossche H, Marichal P, Le Jeune L, Coene MC. Biochemical mechanism of action of ketoconazole on fungi: inhibition of ergosterol biosynthesis. J Antimicrob Chemother. 1988;22(Suppl B):1-14.
2. Vanden Bossche H. Mechanisms of antifungal action: the azole antifungals. Drugs. 1992;44(Suppl 1):1-13.
3. Gupta AK, Lyons DC. The role of topical antifungal agents in the management of seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2014;28(5):609-16.
4. Pierard GE, Arrese JE, Pierard-Franchimont C. Ketoconazole: a multifunctional agent in seborrheic dermatitis and dandruff. Dermatology. 1997;195(Suppl 1):5-7.
5. Gupta AK, Kohli Y, Batra R. In vitro susceptibility of Malassezia species to ketoconazole and other azoles. Med Mycol. 2000;38(5):353-7.
6. Elewski BE. Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol. 2000;43(3 Suppl):S15-21.
7. Cafarchia C, Otranto D. In vitro susceptibility of Malassezia pachydermatis to azole antifungal agents. J Med Microbiol. 2004;53(12):1195-8.
8. Santhanam A, Nazarian R. Topical antifungal medications for skin infections: a review. Curr Probl Dermatol. 2018;54:96-108.
9. Arrese JE, Piérard-Franchimont C, Piérard GE. Malassezia-associated skin diseases and ketoconazole therapy. Dermatology. 2000;201(3):238-41.
10. Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51(Suppl 4):2-15.
11. Gupta AK, Cooper EA. Update on the use of topical antifungal agents. Expert Rev Anti Infect Ther. 2008;6(6):791-802.
12. Sugar AM, Liu XP. In vitro and in vivo interaction of ketoconazole with fungal cell membranes. Antimicrob Agents Chemother. 2000;44(4):985-90.
13. Lepesheva GI, Waterman MR. Sterol 14α-demethylase (CYP51) as a target for antifungal therapy. Biochem Biophys Res Commun. 2007;352(1):1-13.
14. Ameen M. Epidemiology of dermatophytosis and spectrum of fungal pathogens. Clin Dermatol. 2010;28(2):118-26.
15. Batra R, Boekhout T, Guého-Kellermann E, Dawson TL Jr. Malassezia and seborrheic dermatitis: advances in pathophysiology and treatment. Am J Clin Dermatol. 2005;6(6):365-76.
16. Gupta AK, Kohli Y. Evaluation of in vitro susceptibility of dermatophytes to ketoconazole and other antifungals. J Cutan Med Surg. 2003;7(1):7-12.
17. Ellis DH. In vitro susceptibility testing of azole antifungal agents. Dermatology. 2002;204(4):294-301.
18. Leeming JP, Notman FH. Activity of ketoconazole on skin flora and pathogenic fungi. J Med Microbiol. 1987;24(4):363-9.

19. Rooney PJ, Calver GM. Susceptibility of Candida species to ketoconazole. Mycoses. 1990;33(9-10):445-9.
20. Midgley G, Moore MK. Susceptibility profile of Malassezia species to imidazole antifungals. J Med Vet Mycol. 1995;33(2):149-52.
21. Piérard-Franchimont C, Goffin V, Piérard GE. Ketoconazole shampoo in the management of dandruff and seborrheic dermatitis. J Cosmet Dermatol. 2006;5(3):198-204.
22. Schmidt M, Zouboulis CC. Seborrheic dermatitis: pathogenesis and therapy update. Dermatoendocrinol. 2008;1(2):47-53.
23. Levy LA. Safety and efficacy of ketoconazole 2% shampoo in various scalp dermatoses. Cutis. 1997;60(4):239-42.
24. Shuster S. The role of ketoconazole in treatment of tinea versicolor. Br J Dermatol. 1984;111(1):37-41.
25. Faergemann J. Management of pityriasis versicolor with topical ketoconazole formulations. Mycoses. 2000;43(1-2):35-8.
26. Gupta AK, Nicol K. The use of ketoconazole in the treatment of dandruff and seborrheic dermatitis. Skin Therapy Lett. 2004;9(3):1-4.
27. Berk T, Scheinfeld N. Advances in topical antifungal therapy with ketoconazole. J Drugs Dermatol. 2007;6(5):457-62.
28. Crawford F, Hollis S. Topical treatments for fungal skin infections. Cochrane Database Syst Rev. 2007;(4):CD001434.
29. Gupta AK, Versteeg SG, Shear NH. Emerging topical formulations of ketoconazole: improving cutaneous delivery. J Dermatolog Treat. 2015;26(1):83-90.
30. Łabędź W, Pastuszczak M, Wojas-Pelc A. Pityriasis versicolor: current perspectives on epidemiology and management. J Clin Med. 2023;12(3):744.